Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Daiichi Sankyo’s Herceptin Biosimilar Hits Shelves, Nippon Kayaku/Celltrion Earn Breast Cancer Nod
Daiichi Sankyo rolled out its biosimilar version of Herceptin (trastuzumab) on November 28 upon its NHI price listing, pitting itself against Japan’s first such follow-on by Nippon Kayaku/Celltrion, which received an additional breast cancer indication the same day. From the…
To read the full story
Related Article
BUSINESS
- Takeda Says US Revamp “Not Simply Workforce Reduction” as 634 Roles Impacted
April 3, 2026
- New JCR President Confident in 100 Billion Yen Sales Target in 2030s
April 3, 2026
- Meiji Launches Rezurock in Thailand
April 3, 2026
- Mochida, LG Chem Ink Licensing Deal for Dienogest in South Korea, Thailand
April 3, 2026
- Lotte Invests in Rakuten Medical via Biopharma CVC
April 3, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…